Search
for

    Did you mean CTNNB1?
    GlossaryCTNNB1

    gene encoding beta-catenin, crucial for cell signaling and adhesion

    CTNNB1 is a gene that encodes a protein called beta-catenin, which plays a crucial role in cell signaling and adhesion. In simple terms, beta-catenin helps cells stick together and communicate, which is important for tissue development and maintenance. Mutations in CTNNB1 can lead to various medical conditions, including certain types of cancer and developmental disorders.

    Related Terms

    Sort by

    Community Join

    30 / 1000+ results

      community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi

      in Treatment  13 upvotes 6 years ago
      PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

      community GT20029 and PP405 the new fin and min that we been waiting for ?

      in Chat  36 upvotes 11 months ago
      PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

      community Any updates or news on Gt20029?

      in Chat  7 upvotes 1 year ago
      There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

      community cb-03-01 research chem (winlevi/clascoterone cream)

      in Technology  3 upvotes 2 years ago
      The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

      community GT20029 Big Phase 2 Update Results!

      in Research/Science  52 upvotes 6 months ago
      GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

      community CB-03-01 / Breezula Personal Results

      in Treatment  17 upvotes 3 months ago
      The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

      community GT20029 Anageninc Market Availability

      in Research/Science  166 upvotes 3 years ago
      The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

      community Clascoterone - clearnet vendor

      in Chat  2 upvotes 5 months ago
      The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

      community Where is GT20029 already? Grrrr

      in Research/Science  20 upvotes 2 years ago
      The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

      community GT20029. Kintor Pharma’s Product

      in Research/Science  12 upvotes 3 years ago
      The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

      community Difference: GT20029 vs CosmeRNA

      in Treatment  9 upvotes 3 years ago
      GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

      community GT20029 Phase 2 results are out

      in Treatment  60 upvotes 6 months ago
      GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

      community Breaking hair loss news! GT20029 is a resounding success!

      in Product  132 upvotes 2 years ago
      GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

      community Can GT20029's Become The Best Treatment Option?

      in Chat  14 upvotes 3 years ago
      The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

      community TresslessGPT is available to ChatGPT Plus users

      in 📣 Announcement  107 upvotes 2 years ago
      The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

      community Experience with CB (Breezula)?

      in Research/Science  4 upvotes 6 years ago
      CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

      community Wrap it up everyone. CB-03-01 is another failed treatment

      in Treatment  80 upvotes 8 months ago
      CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

      community GT20029 & KX826 Major Updates from Kintor.

      in Research/Science  104 upvotes 1 year ago
      KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

      community Pyrilutamide kintor pharmaceutical

      in Chat  6 upvotes 2 years ago
      The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

      community GT20029 phase II results release date?

      in Research/Science  16 upvotes 2 years ago
      The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

      community GT20029 - Promising phase II results

      in Research/Science  15 upvotes 2 years ago
      GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

      community Bad news about GT20029 from Anagen Inc

      in Treatment  11 upvotes 3 years ago
      The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.